Beckley Psytech

"I believe, in a decade from now, multiple psychedelics will be prescribed as legal medicines for a whole range of psychiatric conditions". In this fascinating interview with Evan Baehr, Beckley Psytech's CEO, Cosmo Feilding Mellen, shares his unique journey from growing up at the heart of the psychedelic revolution to leading the charge in plant-based medicine for conditions like depression and substance abuse. If you're curious about the future of mental health, tune in to learn more. https://lnkd.in/etNEk2Vr

How do you progress a psychedelic-based treatment through development and onto patients in need? That's what our Founder and CEO, Cosmo Feilding Mellen, discussed with Brandon Li on the 'Power to the Patients' podcast, where he covered everything from why shorter treatment duration matters to ethics in psychedelic medicines. Full episode in the comments.

Check out our CEO, Cosmo Feilding Mellen on the ‘Power to the Patients’ podcast where he talks about: 🌱 The founding story of Beckley Psytech 🚀 Our mission to develop effective and accessible medicines for mental health conditions and why we're focusing on next-generation compounds. 🧠 Our recent study results that show a single dose of our lead compound, BPL-003, can produce rapid and lasting effects for people with depression. Click through to listen here: https://lnkd.in/ecpWxput

On #WorldMentalHealthDay, we sat down with our Chief Scientific and Medical Officer, Dr. Rob Conley, to explore the current treatment landscape for mental health conditions and hear his hopes for the next generation of therapies. In this insightful Q+A, he draws on his experience from Beckley Psytech, Eleusis and Eli Lilly and Co, as well as his long academic career at the University of Pittsburgh and University of Maryland School of Medicine, to shed light on: 💊 The challenges with conventional mental health treatments 🧠 Advances in mental health care ✅ The potential of next-generation psychedelic-based solutions Click here to read the full Q+A and learn more about the evolving world of mental health treatments: https://lnkd.in/e6PRxgpf

How might next-generation psychedelics revolutionise mental health treatment? That's exactly what our CEO, Cosmo Feilding Mellen, discussed with Jamie Ducharme at TIME in this piece about the growing psychedelic medicine field. We're proud to be at the forefront of developing effective, rapid-acting and accessible medicines for conditions like depression and substance use disorders. Learn more about our work here: https://lnkd.in/grJTzNWg

Last month, our CEO, Cosmo Feilding Mellen, sat down with Brandon Li, Co-Founder of Power, the Modern Clinical Trial Marketplace, to talk about giving ‘Power to the Patients’. With nearly 1 billion people around the world living with a mental health disorder, and many of them not getting the relief they need from existing medications, we’re on a mission to develop effective, well-tolerated and accessible medicines that deliver rapid and lasting effects with a short time in clinic. Here's a sneak peak of the chat and tune in next week to learn more...

Today, we’re at #ECNP2024 sharing data from our open-label Phase IIa study which investigated the effects of BPL-003, our novel synthetic formulation of 5-MeO-DMT benzoate, in patients with Treatment Resistant Depression. Initial findings from that study showed that: 1) A single administration of BPL-003 demonstrated a rapid antidepressant effect, with 55% of patients having a 50% or greater improvement in depression symptoms the day after dosing (day 2). 2) BPL-003 could produce a robust and lasting antidepressant effect, with 55% of patients meeting the criteria for remission from symptoms of depression at day 29 and 45% in remission at day 85. 3) BPL-003 required a short time in clinic, with patients deemed dischargeable within an average time of less than 2 hours. With several Phase II studies underway investigating BPL-003 further in Treatment Resistant Depression and Alcohol Use Disorder, we are looking forward to learning more about how this novel compound could help people living with mental health conditions. Learn more about our Phase IIa findings and ongoing studies on our website: https://lnkd.in/g4QaUMAC #ECNP2024 #neuroscience #psychiatry

Today is Global Magic Mushroom Day and it’s an opportunity to spotlight the exciting potential of psilocybin and psychedelic fungi as treatments for mental health conditions. At Beckley Psytech, we’re investigating the therapeutic possibilities of psilocin - the active metabolite of psilocybin - in clinical studies of our novel compound ELE-101. We believe our synthetic formulation can produce a shorter, more consistent and more controllable experience than oral formulations of psilocybin. We dosed the first patients in our Phase IIa study of ELE-101 for Major Depressive Disorder in June and you can learn more about the trial here: https://lnkd.in/eGEQdi8h

We are going to be at the European College of Neuropsychopharmacology (ECNP) Congress this week with two poster presentations that will share interesting insights into the workings of BPL-003, our novel, synthetic, intranasal formulation of 5-MeO-DMT benzoate. On Sunday 22nd, we’ll be presenting data from our Phase I study of BPL-003 which compares a sub-perceptual dose of the treatment against a placebo. This is an important area of research addressing the topic of unblinding in clinical studies of psychedelic-based treatments. On Monday 23rd, we’ll be showing findings from our Phase IIa study which investigated the effects of 10mg of BPL-003 in patients with Treatment Resistant Depression. This poster will include evidence of the rapid and lasting antidepressant effects of a single dose of BPL-003. Make sure to pop along and say hello if you are there, or catch us virtually. To learn more about the poster presentations, please click below: https://lnkd.in/eR8FF4Y8 #ECNP2024 #neuroscience #psychiatry

Results from our Phase I study of BPL-003 in healthy volunteers have now been published in Volume 38, Issue 8 of the Journal of Psychopharmacology. The paper shows that BPL-003 was well-tolerated with a rapid onset of subjective effect and resolution of subjective effect within 2 hours, indicating the potential of BPL-003 to deliver a short treatment experience with a reduced resource burden on healthcare systems. Find the full paper here: https://lnkd.in/eGQksdYJ